Anti-Influenza Hyperimmune Intravenous Immunoglobulin Pilot Study (INSIGHT 005: Flu-IVIG Pilot)

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Influenza
Interventions
BIOLOGICAL

Intravenous hyperimmune immunoglobulin (Flu-IVIG)

BIOLOGICAL

Placebo

Trial Locations (11)

10467

Montefiore Medical Center, The Bronx

20037

George Washington University, Washington D.C.

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

43210

Ohio State University Wexner Medical Center, Columbus

45409

Miami Valley Hospital, Dayton

48202

Henry Ford Hospital, Detroit

55905

Mayo Clinic, Rochester

75235

University of Texas Southwestern Medical Center, Dallas

80204

Denver Public Health, Denver

92103

University of California at San Diego, San Diego

08103

Cooper University Hospital, Camden

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02008578 - Anti-Influenza Hyperimmune Intravenous Immunoglobulin Pilot Study (INSIGHT 005: Flu-IVIG Pilot) | Biotech Hunter | Biotech Hunter